Altering the tropism of lentiviral vectors through pseudotyping.
Reads0
Chats0
TLDR
This review samples a few of the more prominent examples from the ever-expanding list of published lentiviral pseudotypes, noting comparisons made with pseudotypes involving VSV-G in terms of titer, viral particle stability, toxicity, and host-cell specificity.Abstract:
The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a process known as pseudotyping Pseudotyped lentiviral vectors consist of vector particles bearing glycoproteins (GPs) derived from other enveloped viruses Such particles possess the tropism of the virus from which the GP was derived For example, to exploit the natural neural tropism of rabies virus, vectors designed to target the central nervous system have been pseudotyped using rabies virus-derived GPs Among the first and still most widely used GPs for pseudotyping lentiviral vectors is the vesicular stomatitis virus GP (VSV-G), due to the very broad tropism and stability of the resulting pseudotypes Pseudotypes involving VSV-G have become effectively the standard for evaluating the efficiency of other pseudotypes This review samples a few of the more prominent examples from the ever-expanding list of published lentiviral pseudotypes, noting comparisons made with pseudotypes involving VSV-G in terms of titer, viral particle stability, toxicity, and host-cell specificity Particular attention is paid to publications of successfully targeting a specific organ or cell typesread more
Citations
More filters
Journal ArticleDOI
Quantification of HIV-based lentiviral vectors: influence of several cell type parameters on vector infectivity
TL;DR: It is proposed that determination of the amount of integrated viral DNA by quantitative PCR be used in combination with the reporter gene expression assay to evaluate different methods of lentiviral vector titration.
Journal ArticleDOI
Infectious titer determination of lentiviral vectors using a temporal immunological real-time imaging approach.
TL;DR: In this article, an immunological real-time imaging method was developed to quantify the infectious titer of anti-CD19 CAR lentiviral vectors with a temporal readout using the Incucyte® S3 live-cell analysis system.
Journal ArticleDOI
Diverse viral glycoproteins as well as CD4 co-package into the same human immunodeficiency virus (HIV-1) particles.
TL;DR: Glycoproteins that are actively incorporated into HIV-1 virions are efficiently co-packaged into the same virus particles, suggesting that the same general mechanism for recruitment may act in many viruses.
Journal ArticleDOI
Vpx mediated degradation of SAMHD1 has only a very limited effect on lentiviral transduction rate in ex vivo cultured HSPCs
Duo Li,Erika Schlaepfer,Annette Audigé,Mary-Aude Rochat,Sandra Ivic,Caitlin N. Knowlton,Baek Kim,Oliver T. Keppler,Roberto F. Speck +8 more
TL;DR: This paper showed that degrading SAMHD1 in myeloid and resting CD4+ T cells would result in more efficient lentiviral transduction rates in HSPCs, and used viral like particles (VLPs) containing Vpx, shRNA against SAMHD 1, or provided an excess of dNTPs or dNs to study this question.
Journal Article
Vpx mediated degradation of SAMHD1 has only a very limited effect on lentiviral transduction rate in ex vivo cultured HSPCs
Duo Li,Erika Schlaepfer,Annette Audigé,Mary-Aude Rochat,Sandra Ivic,Caitlin N. Knowlton,Baek Kim,Oliver T. Keppler,Roberto F. Speck +8 more
TL;DR: The data suggest that SAMHD1 has some limited efficacy in blocking reverse transcription but the major barrier for efficient lentiviral transduction occurs before reverse transcription.
References
More filters
Journal ArticleDOI
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Luigi Naldini,Ulrike Blömer,Philippe Gallay,Daniel S. Ory,Richard C. Mulligan,Fred H. Gage,Inder M. Verma,Didier Trono +7 more
TL;DR: The ability of HIV-based viral vectors to deliver genes in vivo into nondividing cells could increase the applicability of retroviral vectors in human gene therapy.
Journal ArticleDOI
Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells
TL;DR: The ability to concentrate vesicular stomatitis virus G glycoprotein pseudotyped vectors will facilitate gene therapy model studies and other gene transfer experiments that require direct delivery of vectors in vivo, and facilitate genetic studies in nonmammalian species, including the important zebrafish developmental system.
Journal ArticleDOI
A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes
TL;DR: A human 293-derived retroviral packaging cell line (293GPG) capable of producing high titers of recombinant Moloney murine leukemia virus particles that have incorporated the vesicular stomatitis virus G (VSV-G) protein is generated.
Journal ArticleDOI
Identification of α-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus
Wei Cao,Michael D. Henry,Persephone Borrow,Hiroki Yamada,John H. Elder,Eugene V. Ravkov,Stuart T. Nichol,Richard W. Compans,Kevin P. Campbell,Michael B. A. Oldstone +9 more
TL;DR: A peripheral membrane protein that is interactive with lymphocytic choriomeningitis virus (LCMV) was purified from cells permissive to infection and determined to be alpha-dystroglycan (alpha-DG).
Journal ArticleDOI
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model
Mimoun Azzouz,G. Scott Ralph,Erik Storkebaum,Lucy E. Walmsley,Kyriacos A. Mitrophanous,Susan M. Kingsman,Peter Carmeliet,Nicholas D. Mazarakis +7 more
TL;DR: It is reported that a single injection of a VEGF-expressing lentiviral vector into various muscles delayed onset and slowed progression of ALS in mice engineered to overexpress the gene coding for the mutated G93A form of the superoxide dismutase-1 (SOD1G93A).
Related Papers (5)
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Salima Hacein-Bey-Abina,C von Kalle,C von Kalle,Manfred Schmidt,Matthew P. McCormack,NM Wulffraat,Philippe Leboulch,Annick Lim,Cameron S. Osborne,R. Pawliuk,Estelle Morillon,R. Sorensen,A. Forster,Peter Fraser,Jeffrey I. Cohen,G de Saint Basile,Ian E. Alexander,Uwe Wintergerst,Thierry Frebourg,Alain Aurias,Dominique Stoppa-Lyonnet,Serge Romana,I. Radford-Weiss,Fabian Gross,Françoise Valensi,Eric Delabesse,Elizabeth Macintyre,F. Sigaux,Jean Soulier,L. E. Leiva,Manuela Wissler,Claudia Prinz,Terence H. Rabbitts,F. Le Deist,Alain Fischer,Marina Cavazzana-Calvo +35 more